4DMEDICAL LIMITED (4DX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

4DX

4DX - 4DMEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.1
Index: ALL-ORDS | ALL-TECH

4DMedical is a global medical technology company specialising in the treatment of lung disease through respitory imaging and analysis. The company has facilities in Melbourne and Los Angeles. It listed on the ASX in 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.59

10 Sep
2025

-0.085

OPEN

$1.61

-5.07%

HIGH

$1.79

19,275,018

LOW

$1.52

TARGET
$0.905 -43.1% downside
OTHER COMPANIES IN THE SAME SECTOR
AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
4DX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 14.0 - 4.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-14.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx5.9 M
Book Value Per Share xxxxxxxxxxxxxxx13.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-34.5 M
Net Profit Margin xxxxxxxxxxxxxxx-513.72 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-44.49 %
Return on Invested Capital xxxxxxxxxxxxxxx-42.19 %
Return on Assets xxxxxxxxxxxxxxx-27.99 %
Return on Equity xxxxxxxxxxxxxxx-44.49 %
Return on Total Capital xxxxxxxxxxxxxxx-66.61 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-34.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx1.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx4.84 %
Cost of Goods Sold xxxxxxxxxxxxxxx38 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx16 M
Research & Development xxxxxxxxxxxxxxx2 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

01/08/2025

1

Speculative Buy

$0.76

-52.20%

Ord Minnett highlights a $10m strategic investment from Pro Medicus ((PME)) in 4DMedical as a timely capital injection.

This move by Pro Medicus will boost 4DMedical's cash balance to around $17m. It should also provide commercial validation ahead of the CT:VQ (Ventilation/Perfusion imaging using Computed Tomography) launch in the US, suggest the analysts.

The investment, structured as a hybrid debt-equity loan, includes a two-year maturity with repayment of $12.5m or $20m if the share price doubles, plus an equity kicker.

Ord Minnett sees this as a strong endorsement of CT:VQ, with a total addressable market over US$1.1bn.

The broker observes 4Q25 results showed 388 installed sites and around 74,000 scans, up 7% and 35% quarter-on-quarter, respectively. FY25 revenue rose 56% to $5.9m with gross margins above 90%, and net operating cash outflow improved to -$9.5m.

The analysts remind investors the company still requires stronger revenue in 1H26 and a successful CT:VQ launch, with FDA approval expected in 1H26.

Ord Minnett lowers its target price to 75c from 76c and retains a Speculative Buy rating.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

4DX STOCK CHART

FNArena News on 4DX

1
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 03-09-2025

Sep 03 2025 - Australia
3
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
4
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
5
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia